Abbott Laboratories
General ticker "ABT" information:
- Sector: Health Care
- Industry: Medical - Devices
- Capitalization: $224.3B (TTM average)
Abbott Laboratories does not follow the US Stock Market performance with the rate: -2.4%.
Estimated limits based on current volatility of 0.9%: low 122.09$, high 124.40$
Factors to consider:
- Earnings expected soon, date: 2026-01-22 bmo
- Company included in S&P500 list
- Company pays dividends (quarterly): last record date 2025-10-15, amount 0.59$ (Y1.94%)
- Total employees count: 114000 as of 2024
- US accounted for 0.0% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Geopolitical risks, Cybersecurity threats, Pandemic risks, R&D failure, Liquidity and credit risks
- Price in estimated range
- Earnings for 9 months up through Q3 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [99.58$, 135.69$]
- 2025-12-31 to 2026-12-31 estimated range: [105.22$, 143.07$]
Financial Metrics affecting the ABT estimates:
- Negative: with PPE of 24.4 at the end of fiscal year the price was high
- Positive: 7.54 < Operating profit margin, % of 16.27
- Positive: Return on assets ratio (scaled to [-100,100]) of 14.13 > 6.04
- Negative: negative Industry operating cash flow (median)
- Positive: 42.53 < Shareholder equity ratio, % of 58.55 <= 64.17
- Positive: Interest expense per share per price, % of 0.28 <= 0.74
- Positive: -4.41 < Investing cash flow per share per price, % of -1.19
- Positive: 0.04 < Operating cash flow per share per price, % of 4.34
Short-term ABT quotes
Long-term ABT plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $43,653.00MM | $40,109.00MM | $41,950.00MM |
| Operating Expenses | $35,291.00MM | $33,631.00MM | $35,125.00MM |
| Operating Income | $8,362.00MM | $6,478.00MM | $6,825.00MM |
| Non-Operating Income | $-56.00MM | $186.00MM | $188.00MM |
| Interest Expense | $558.00MM | $637.00MM | $559.00MM |
| R&D Expense | $2,888.00MM | $2,741.00MM | $2,844.00MM |
| Income(Loss) | $8,306.00MM | $6,664.00MM | $7,013.00MM |
| Taxes | $1,373.00MM | $941.00MM | $-6,389.00MM |
| Profit(Loss)* | $6,933.00MM | $5,723.00MM | $13,402.00MM |
| Stockholders Equity | $36,686.00MM | $38,603.00MM | $47,664.00MM |
| Inventory | $6,173.00MM | $6,570.00MM | $6,194.00MM |
| Assets | $74,438.00MM | $73,214.00MM | $81,414.00MM |
| Operating Cash Flow | $9,581.00MM | $7,261.00MM | $8,558.00MM |
| Capital expenditure | $1,777.00MM | $2,202.00MM | $2,207.00MM |
| Investing Cash Flow | $-1,740.00MM | $-3,133.00MM | $-2,338.00MM |
| Financing Cash Flow | $-7,636.00MM | $-7,091.00MM | $-5,404.00MM |
| Earnings Per Share** | $3.95 | $3.30 | $7.74 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.